PATENT CLAIM ANALYSIS

Application Number: 16017974
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "136100"]

Abstract:
The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

Claim (Index 40):
The method of  claim 39 , wherein the condition is a cancer.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 94.0
- Lexical Diversity: 2.10145
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15085644', '15878344', '15085317', '15160742', '15402807']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8597950843354606
- 35 USC 102 Novelty (BERT): 0.6846371119366728
- Combined Prediction Score: 0.8422792870955818
- Mean Citation Score: 781.675702
- Max Citation Score: 1126.2704
- Similarity Product: 696.9128115736007

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test